Title :

Allogeneic hematopoietic cell transplantation in patients with therapy-related myeloid neoplasm after breast cancer: a study of the Chronic Malignancies Working Party of the EBMT.

Author(s) :

Nabergoj, M. [Auteur]
Mauff, K. [Auteur]
Beelen, D. [Auteur]
Ganser, A. [Auteur]
Kröger, N. [Auteur]
Stölzel, F. [Auteur]
Finke, J. [Auteur]
Passweg, J. [Auteur]
Cornelissen, J. [Auteur]
Schub, N. [Auteur]
Veelken, J. H. [Auteur]
Beguin, Y. [Auteur]
Wilson, K. [Auteur]
Zuckerman, T. [Auteur]
Hunault-Berger, Mathilde [Auteur]
Centre Hospitalier Universitaire d'Angers [CHU Angers]
Lioure, Bruno [Auteur]
Institut de Cancérologie de Strasbourg Europe [ICANS]
Porras, R. P. [Auteur]
Turlure, Pascal [Auteur]
CHU Limoges
Kerre, T. [Auteur]
Koster, L. [Auteur]
Hayden, P. J. [Auteur]
Onida, F. [Auteur]
Scheid, C. [Auteur]
Chalandon, Y. [Auteur]
Robin, Marie [Auteur]
Hopital Saint-Louis [AP-HP] [AP-HP]
Yakoub-Agha, Ibrahim [Auteur]
Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Journal title :

Bone Marrow Transplantation

Abbreviated title :

Bone Marrow Transplant

Volume number :

57

Pages :

1072–1078

Publication date :

2022-04-25

ISSN :

1476-5365

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first ...
Show more >We performed a registry study on therapy-related myeloid neoplasm (t-MN), both therapy-related myelodysplastic syndrome (t-MDS) and acute myeloid leukemia (t-AML) following treatment for breast cancer who underwent a first allogeneic hematopoietic cell transplant (allo-HCT). Of 252 identified female patients (median age 57 years), 77% were transplanted for t-AML and 23% for t-MDS, with a median time from breast cancer diagnosis to the diagnosis of tMN and subsequent allo-HCT of 3.7 and 4.6 years, respectively. At transplant, 191 patients were in remission for breast cancer, while 4 were not (57 missing). T-MN was in a complete remission at the time of transplant in 67% of patients. 2-year overall survival, relapse free-survival, relapse incidence and non-relapse mortality were 50%, 45%, 33%, and 22%, respectively. Multivariable analysis revealed that if the t-MN was not in CR pre-transplant, this was associated with lower OS, RFS, and a higher relapse incidence. Seventeen cases of breast cancer recurrence were recorded after a median of 2.4 years post-transplant, and relapse of primary breast cancer accounted for 7% of deaths. This study indicates that allo-HCT for t-MN following treatment for breast cancer shows encouraging transplant outcomes. The incidence of breast cancer relapse post-transplant remains a cause for concern.Show less >

Language :

Anglais

Audience :

Internationale

Popular science :

Non

Administrative institution(s) :

Université de Lille
Inserm
CHU Lille

Collections :

• Institut de Recherche Translationnelle sur l'Inflammation (INFINITE) - U1286

Submission date :

2024-01-12T01:41:35Z
2024-03-22T07:50:51Z